525 related articles for article (PubMed ID: 23369845)
21. Primary antifungal prophylaxis: decrease of invasive fungal disease incidence and reduction of risk factors in haematological patients in a 5-year retrospective study.
Li Y; Liu M; Zhai B; Zhao X; Wang L; Li H; Wang S; Zhu H; Wang Q; Gao C; Huang W; Yu L
Intern Med J; 2018 Jun; 48(6):713-720. PubMed ID: 29230923
[TBL] [Abstract][Full Text] [Related]
22. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study.
León C; Ruiz-Santana S; Saavedra P; Galván B; Blanco A; Castro C; Balasini C; Utande-Vázquez A; González de Molina FJ; Blasco-Navalproto MA; López MJ; Charles PE; Martín E; Hernández-Viera MA;
Crit Care Med; 2009 May; 37(5):1624-33. PubMed ID: 19325481
[TBL] [Abstract][Full Text] [Related]
23. [Invasive fungal infection in critically ill patients].
Garnacho-Montero J; Díaz-Martín A; Ruiz-Pérez De Piappón M; García-Cabrera E
Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):338-43. PubMed ID: 22503211
[TBL] [Abstract][Full Text] [Related]
24. Problematic Dichotomization of Risk for Intensive Care Unit (ICU)-Acquired Invasive Candidiasis: Results Using a Risk-Predictive Model to Categorize 3 Levels of Risk From a Multicenter Prospective Cohort of Australian ICU Patients.
Playford EG; Lipman J; Jones M; Lau AF; Kabir M; Chen SC; Marriott DJ; Seppelt I; Gottlieb T; Cheung W; Iredell JR; McBryde ES; Sorrell TC
Clin Infect Dis; 2016 Dec; 63(11):1463-1469. PubMed ID: 27601224
[TBL] [Abstract][Full Text] [Related]
25. Pre-emptive diagnosis and treatment of fungal infections--evaluation of a single-centre policy.
Schneider T; Halter J; Heim D; Passweg J; Stern M; Tichelli A; Weisser M; Gerull S
Clin Microbiol Infect; 2012 Feb; 18(2):189-94. PubMed ID: 21729194
[TBL] [Abstract][Full Text] [Related]
26. Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia.
Fung M; Kim J; Marty FM; Schwarzinger M; Koo S
PLoS One; 2015; 10(11):e0140930. PubMed ID: 26554923
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
Sohn HS; Lee TJ; Kim J; Kim D
Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
[TBL] [Abstract][Full Text] [Related]
28. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.
Shepherd J; Jones J; Frampton GK; Tanajewski L; Turner D; Price A
Health Technol Assess; 2008 Jun; 12(28):iii-iv, ix-95. PubMed ID: 18547499
[TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections.
de Vries R; Daenen S; Tolley K; Glasmacher A; Prentice A; Howells S; Christopherson H; de Jong-van den Berg LT; Postma MJ
Pharmacoeconomics; 2008; 26(1):75-90. PubMed ID: 18088160
[TBL] [Abstract][Full Text] [Related]
30. Failure of empirical systemic antifungal therapy in mechanically ventilated critically ill patients.
Bailly S; Bouadma L; Azoulay E; Orgeas MG; Adrie C; Souweine B; Schwebel C; Maubon D; Hamidfar-Roy R; Darmon M; Wolff M; Cornet M; Timsit JF
Am J Respir Crit Care Med; 2015 May; 191(10):1139-46. PubMed ID: 25780856
[TBL] [Abstract][Full Text] [Related]
31. A Risk Prediction Model for Invasive Fungal Disease in Critically Ill Patients in the Intensive Care Unit.
Li F; Zhou M; Zou Z; Li W; Huang C; He Z
Asian Nurs Res (Korean Soc Nurs Sci); 2018 Dec; 12(4):299-303. PubMed ID: 30472388
[TBL] [Abstract][Full Text] [Related]
32. Common invasive fungal diseases: an overview of invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis pneumonia.
Schmiedel Y; Zimmerli S
Swiss Med Wkly; 2016; 146():w14281. PubMed ID: 26901377
[TBL] [Abstract][Full Text] [Related]
33. Posaconazole: a pharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts.
Lyseng-Williamson KA
Pharmacoeconomics; 2011 Mar; 29(3):251-68. PubMed ID: 21309616
[TBL] [Abstract][Full Text] [Related]
34. ÉPICO project. Development of educational recommendations using the DELPHI technique on invasive candidiasis in non-neutropenic critically ill adult patients.
Zaragoza R; Llinares P; Maseda E; Ferrer R; Rodríguez A;
Rev Esp Anestesiol Reanim; 2013; 60(7):e1-e18. PubMed ID: 23911095
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
Schonfeld W; Wang Cheng J; Tong KB; Seifeldin R
Clin Ther; 2008 May; 30(5):964-73. PubMed ID: 18555943
[TBL] [Abstract][Full Text] [Related]
36. An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis.
Soares MO; Welton NJ; Harrison DA; Peura P; Shankar- Hari M; Harvey SE; Madan JJ; Ades AE; Palmer SJ; Rowan KM
Health Technol Assess; 2012; 16(7):1-186. PubMed ID: 22361003
[TBL] [Abstract][Full Text] [Related]
37. Posaconazole prophylaxis--impact on incidence of invasive fungal disease and antifungal treatment in haematological patients.
Peterson L; Ostermann J; Rieger H; Ostermann H; Rieger CT
Mycoses; 2013 Nov; 56(6):651-8. PubMed ID: 23710592
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain.
Grau S; de la Cámara R; Sabater FJ; Jarque I; Carreras E; Casado MA; Sanz MA
BMC Infect Dis; 2012 Apr; 12():83. PubMed ID: 22471553
[TBL] [Abstract][Full Text] [Related]
39. A multicentre, randomised controlled trial comparing the clinical effectiveness and cost-effectiveness of early nutritional support via the parenteral versus the enteral route in critically ill patients (CALORIES).
Harvey SE; Parrott F; Harrison DA; Sadique MZ; Grieve RD; Canter RR; McLennan BK; Tan JC; Bear DE; Segaran E; Beale R; Bellingan G; Leonard R; Mythen MG; Rowan KM
Health Technol Assess; 2016 Apr; 20(28):1-144. PubMed ID: 27089843
[TBL] [Abstract][Full Text] [Related]
40. Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature.
Dixon S; McKeen E; Tabberer M; Paisley S
Pharmacoeconomics; 2004; 22(7):421-33. PubMed ID: 15137881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
